Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP14 | P54578 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.37 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.36 |
| ▸ | XIAP | P98170 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503872 | 0.89 | USP14 (0.48) | USP14KDM4EHIF1APTGDRMEN1 | |
| SCHEMBL503558 | 0.88 | MEN1 (0.44) | USP14TP53KDM4EMDM2PTGDR | |
| SCHEMBL503756 | 0.88 | USP14 (0.45) | USP14KDM4EHIF1ABCL2MDM2 | |
| SCHEMBL334235 | 0.87 | BCL2 (0.42) | USP14KDM4EBCL2MDM2MCL1 | |
| SCHEMBL333497 | 0.86 | USP14 (0.44) | USP14KDM4EHIF1ABCL2MDM2 | |
| SCHEMBL333231 | 0.86 | MEN1 (0.48) | USP14TP53KDM4EHIF1AMEN1 | |
| SCHEMBL503499 | 0.86 | MDM2 (0.45) | USP14KDM4EBCL2MDM2MCL1 | |
| SCHEMBL335371 | 0.85 | USP14 (0.41) | USP14TP53KDM4EHIF1ABCL2 | |
| SCHEMBL334268 | 0.84 | KDM4E (0.41) | USP14TP53KDM4EBCL2MDM2 | |
| SCHEMBL334350 | 0.84 | PTGES (0.52) | KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SW) | 2012-02-02 | — | — | US | disclosed |
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SW) | 2012-02-02 | — | — | US | disclosed |
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SW) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | LTC4S, LTB4R2, LTB4R | USP14 2929/4885TP53 2801/4885KDM4E 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.